New Research on Bi-directional Tachycardia Drugs Being Developed By Leading Companies For Treatment Of Cardiovascular Diseases During 2020-2028
Research Nester released a report titled “Bi-directional Tachycardia Drugs Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers detailed overview of the global bi-directional tachycardia drugs market in terms of market segmentation by product, route of administration, distribution channel and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
The bi-directional tachycardia drugs are used for the treatment of cardiovascular diseases in adult patients. Owing to its wide-scale application for the treatment of growing rate of cardiac disorders such as tachycardia, heart-attack and arrhythmia, the bi-directional tachycardia drugs market is anticipated to record a significant CAGR throughout the forecast period, i.e., 2020-2028. The market is segmented by distribution channel into hospitals, clinics, research laboratories and retail pharmacies, out of which, the segment for hospitals is anticipated to hold the leading share in the market. This can be attributed to its huge availability of bi-directional tachycardia drugs which are used for the patient’s treatment at the hospital only under the doctors’ supervision.
Regionally, the global bi-directional tachycardia drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market for bi-directional tachycardia drugs in North America is predicted to hold the highest share in the market on account of government support in healthcare expenditure and adoption of advanced therapeutics as well as presence of prominent market players in the region which manufacture and market bi-directional tachycardia drugs.
Growing Incidence Rate of Cardiovascular Diseases To Boost The Market Growth
According to the American Heart Association (AHA), cardiovascular disease is the leading global cause of death, accounting for more than 17.6 million deaths per year in 2016 which is expected to cross 23.6 million by the end of 2030.
The demand for bi-directional tachycardia drugs is high as the rate of cardiovascular diseases among people is constantly increasing across the world. Further, prevalence of heart diseases among geriatric population and changing lifestyles as well as the huge investment in healthcare infrastructure is anticipated to increase the market growth of bi-directional tachycardia drugs over the forecast period.
However, the high cost of the drugs involved in the treatment of heart disorders coupled with its side-effects is estimated to hamper the market growth.
This report also provides the existing competitive scenario of some of the key players of the global bi-directional tachycardia drugs market which includes company profiling of Pfizer Inc. (NYSE:PFE), Novartis AG, Bristol-Myers Squibb Company (NYSE:BMY), Eli Lilly and Company (NYSE:LLY), AstraZeneca (LSE:AZN), GlaxoSmithKline plc. (LSE:GSK), Merck and Co., Inc. (NYSE:MRK), Sanofi and Bayer AG.
The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global bi-directional tachycardia drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.